Page 1

botanix PHARMACEUTICALS 23 July 2021 Botanix Pharmaceuticals Quarterly Activities Report and 4C Quarterly Cash Flow Report Key highlights • Successful launch of BTX 1702 rosacea clinical study , currently under COVID related restrictions , with sites initiated in Australia , and New Zealand start up pending Encouraging results achieved from the BTX 1204A pilot study of canines with atopic dermatitis , with preparation underway to commence a proof of concept canine study Preparation for the BTX 1801 Phase 2b clinical study targeting the nasal decolonisation of Staph aureus in haemodialysis patients to prevent bloodstream infections is well progressed and expected to initiate in 4Q CY2021 Support for Botanix's research on the antimicrobial potential of cannabidiol published by a leading South American academic group in BioRxiv Actively reviewing a number of opportunities to leverage the unique properties of the Permetrex ™ technology platform to deliver new dermatology drugs Botanix in a strong financial position , holding cash balance of A $ 21.6m at 30 June 2021 Philadelphia PA and Perth Australia , 23 July 2021 : Clinical dermatology company , Botanix Pharmaceuticals Limited ( ASX : BOT , “ Botanix ” or “ the Company ” ) , is pleased to release its Quarterly Activities Report and Appendix 4C Quarterly Cash Flow report for the period ended 30 June 2021 . Clinical studies and drug development Rosacea : BTX 1702 Phase 1b clinical study underway Following ethics approval , Botanix launched its BTX 1702 Phase 1b rosacea clinical study in June . The study is a randomised , double blind , vehicle - controlled study in patients with moderate to severe papulopustular rosacea and will investigate the safety and tolerability of two different concentrations of BTX 1702 along with a vehicle ( control ) arm in adults over an 8 - week treatment period . The study plans to enrol approximately 120 patients in 12 dermatology clinical sites across Australia and New Zealand . Botanix launched the BTX 1702 rosacea clinically study , currently under COVID related restrictions , during the quarter with sites already initiated in Australia and currently recruiting patients and the first site in New Zealand expected to be initiated in the near term . Additional sites are being reviewed to potentially speed up recruitment , if lockdowns continue intermittently throughout the planned study duration . - The BTX 1702 clinical study has been designed to enable increased data capture , as well as to provide additional insights to support Botanix's broader dermatology platform . This includes universal use of advanced Canfield imaging technology to support clinical assessments and improve patient tracking , as well as centralised review of each investigator's ratings for patient inclusion and some endpoint assessments . The Company believes that these process and technology improvements to the study